menu ☰
menu ˟

Compared with adalimumab, baricitinib demonstrated better efficacy for RA

16 Feb 2017
In patients with rheumatoid arthritis who had an inadequate response to methotrexate, the oral Janus kinase inhibitor baricitinib demonstrated better efficacy through 52 weeks compared with adalimumab, according to recently published data.“This is ...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.